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TP53 accumulation in human primary breast carcinomas was 
studied by a quantitative luminometric immunoassay (LIA), and 
TP53 gene alterations, exons 5-8, were examined by single* 
strand conformation polymorphism (SSCP) analysis. In 48 of 
142 breast tumor samples, a TPS3 gene alteration was identi* 
fied. In tumor samples without a TPS3 gene alteration, the 
median cytosolic TP53 protein level, as determined by LIA, was 
0.4 ng/mg protein (range 0-70.8 ng/mg protein), whereas the 
median TP53 protein level for tumor samples with a TP53 gene 
alteration was 10 times higher, i.e., 4.1 ng/mg protein (range
0.1-176.0 ng/mg protein). Despite a significant correlation 
between the outcome of LIA and SSCP, a disagreement was 
found in 22% of cases analyzed. Significant correlations were 
found between TP53 protein accumulation and low estrogen 
receptor content, and with a shorter relapse-free as well as 
overall survival, with a median duration of follow-up of 100 
months. Due to its rapid and easy performance on routinely 
prepared cytosols, the LIA for TP53 protein may be useful in 
evaluating the prognostic impact of TP53 protein accumulation 
in human primary breast cancer.
© 1996 Wiley-Liss, Inc.
Mutations in the tumor-suppressor gene TP53 are the most 
common genetic alterations in human cancers (Hollstein et ah, 
1991; Levine et al, 1991). The human tumor-suppressor TP53 
gene is located on chromosome 17pl3.1 and encodes for a 
53-kDa nuclear phosphoprotein which is implicated in regula­
tion of normal cell growth, division and apoptosis (Levine et 
al, 1991; Lane, 1994). The 20-kb TP53 gene consists of 11 
exons, of which exons 2-11 code for a protein of 393 amino- 
acid residues (Lane, 1994). Exons 2-4 code for the acidic 
N-terminal domain of the TP53 protein, which is involved in 
the transcriptional control of other cellular genes, either 
directly or indirectly via interaction with other proteins (Lane, 
1994). Exons 5-9 code for the central hydrophobic core of the 
protein, which is characterized by its conformational flexibility 
and ability to fold into a domain with sequence-specific 
DNA-binding activity (Cho et al.f 1994). Exons 10 and 11 
specify the more basic C-terminus of the molecule, containing 
motifs involved in nuclear localization and in oligomerization 
(Sturzbecher and Deppert, 1994).
More than 90% of the TP53 gene mutations in tumor cells 
appear to be confined to the phylogeneticaliy conserved exons 
5-8. Except for stop codon mutations and deletions, leading to 
the expression of a truncated protein, these mutations give rise 
to a conformationally altered protein, which is due to a 
prolonged half-life, often stably expressed at high levels 
(Hollstein et al, 1991; Lane, 1994). The mutated TP53 protein 
forms oligomeric complexes with the wild-type protein and, as 
a consequence, can abrogate its normal function. Likewise, 
wild-type TP53 protein can be inactivated by binding to viral 
oncoproteins, such as adenovirus E1B and human papillomavi­
rus E6 proteins. An additional mechanism for inactivation of 
wild-type TP53 which occurs relatively common in breast 
cancer is loss of heterozygosity involving the TP53 gene locus. 
Furthermore, the heterologous interaction of the murine
double-minute protein MDM2 and heat shock protein HSP70 
with wild-type TP53 protein can also result in loss of TP53 
function (Calderwood, 1992; reviewed by Greenblatt et al., 
1994).
Numerous investigations have been performed to analyze 
either the relationship between TP53 protein accumulation 
and TP53 gene mutation or the clinical significance of TP53 
protein accumulation in many tumor types (Bodner et a l, 
1992). In mammaiy cancers, TP53 gene status has been 
assessed at the level of the gene by (constant) denaturant gel 
electrophoresis (CDGE/DGGE), single-strand conformation 
polymorphism (SSCP) analysis and DNA-sequencing tech­
niques, whereas TP53 protein levels have been analyzed by 
immunohistochemical methods, quantitative immunoassays 
(ELISA) or Western blotting (Vojtesek et a l, 1992; Elledge 
and Allzed, 1994). In the present study, we examined TP53 
protein accumulation in cytosols, prepared for steroid hor­
mone receptor analysis, of human primary breast carcinomas 
using a recently developed quantitative luminometric immuno­
assay (LIA) (Borg et a l, 1995). We have correlated TP53 
protein levels with TP53 gene alteration as determined by 
SSCP analysis in the same tumor samples. TP53 protein levels 
were also correlated with clinical outcome to evaluate the 
prognostic significance of TP53 protein accumulation in hu­
man primary breast cancer,
MATERIAL AND METHODS
Patients and tumor samples
The present study includes 142 human primary breast tumor 
specimens, used for routine steroid hormone receptor analysis. 
All clinical data, including age, menopausal status, tumor size, 
lymph-node status, differentiation grade and steroid hormone 
receptor status, were available for 111 patients and are shown 
in Table I. Included were patients without signs of distant 
metastasis at diagnosis. Patients did not receive endocrine 
therapy, chemo- and/or radiotherapy before surgety. Median 
follow-up of patients was 100 (range 47-159) months. Tumor 
tissues were stored in liquid nitrogen, pulverized in the frozen 
state and homogenized in standard receptor buffer according 
to the revised standards of the EORTC Breast Cancer Coop­
erative Group (1980). Cytosols were aliquoted and stored at 
—80°C until further analysis.
SSCP analysis
DNA was isolated from an aliquot of the total tissue 
homogen ate as described previously (Berns et al., 1992) and
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TABLE I -  CHARACTERISTICS OF PATIENTS, TUMORS AND TREATMENT
(111 CASES)
Patients Number of cases
TP53
over-expression
w vaÎue
Total 111 28
Age (yr)
NS2Mean 57.9
Range 28-82
Menopausal status
NSPre 39 31
Post 72 26
Tumours
Size (cm)
<2 29 17 NS
2-5 64 27
>5 18 50
Nodal status3
NO 37 24 NS
Nl-3 37 30
N >3 35 29
Differentiation grade3
Well 2 NS
Moderately 27 19
Poorly 65 31
Hormone receptor status3
E R - 4 28 50
ER + 83 20 0.03
P g R -4 33 46
PgR-f 73 21 NS
Treatment
Surgery of primary tumours
Breast conserving therapy 30
Modified mastectomy 81
Axillary dissection
Yes 108
No 3
Radiotherapy
Breast 52
Axilla 53
Other lymph-node areas 94
Systemic adjuvant treatment
Hormonal therapy 6
Chemotherapy 20
•Percentage of cases with TP53 protein expression above the 
cut-off point (>2.5  ng/mg p ro te in )-2NS, not significant -  
3Numbers do not always add up to i l l  due to missing information-  
4Cut-off points: 10 fmol/mg protein.
subsequently amplified by PCR using primer panels flanking 
exons 5-8 of the TP53 gene (Clontech, Palo Alto, CA). SSCP 
analysis was performed as described by Orita et al (1989). 
Mutations found by PCR-SSCP analysis were confirmed in an 
additional experiment with a second independent PCR prod­
uct. Neutral polymorphism in PCR fragments from exon 6 
(codon 213) was verified by PCR-SSCP and Taql restriction 
analysis.
LIA
TP53 protein levels in cytosols were determined using a 
novel LIA from Sangtec Medical (Bromma, Sweden), as 
described by Borg et al. (1995). The assay was performed on an 
LIA-MAT S300 analyzer (Stratec, Dietzenbach, Germany), 
equipped with a pipetting station, incubator, washer and 
luminometer. In brief, either 100 jjlI standard (range 0-80 ng 
TP53 protein /ml) sample or control and 100 pi tracer (ABEI- 
conjugated monoclonal antibody [MAb] D O l [21]) solution 
were pipetted into tubes coated with pAB1801 MAb (Banks et 
al., 1986). After incubation for 18 hr at room temperature, 
tubes were washed 3 times with 2 ml 0.9% sodium chloride, 
and chemiluminescence was subsequently measured using an 
LIA-MAT starter service kit (Byk-Sangtec Diagnostica, Diet-
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F i g u r e  1 -  Representative p53 LIA standard curve, using known 
amounts of recombinant human TP53 protein. The standard 
xiints are the result of duplicate assays (coefficient of variation, 
Delow 10%). RLU, relative light units.
zenbach, Germany), All samples were diluted in kit diluent 
buffer to a final concentration of 0.5 mg/ml cytosol protein and 
analyzed in duplicate. The TP53 protein concentration was 
expressed in ng/mg protein. A representative standard curve 
of the TP53 LIA is shown in Figure 1. Cytosols of the human 
breast carcinoma cell line T-47D, which contains a mutation in 
exon 6 (codon 194) of the TP53 gene (Nigro et al, 1989), were 
used as control for TP53 protein over-expression. Cell line 
ZR-75.1, without a TP53 gene mutation served as control for 
low TP53 protein expression.
Statistical analysis
To study relations between patient and tumor characteris­
tics and TP53 protein, we used Spearman rank correlations 
when variables were continuous and Kruskal-Wallis or Wil- 
coxon rank sum for categorized variables. Isotonic regression 
analysis was performed to determine the optimal cut-off level 
for TP53 expression (Barlow et al, 1972). For comparison of 
the results of both PCR-SSCP and LIA, the 2-sample Wil- 
coxon rank sum test was applied. Overall and relapse-free 
survival probabilities were calculated by the actuarial method 
of Kaplan and Meier (1958). The Cox proportional hazard 
model was used for univariate and multi-variate survival 
analyses.
RESULTS
TP53 protein expression analysis by LIA
LIA for TP53 protein was performed on 142 primary breast 
tumor cytosols. TP53 protein concentrations ranged from 0 to
176.0 ng/mg protein, with a mean value of 5.8 ng/mg (SD 19.2 
ng/mg) and a median value of 0.5 ng/mg cytosolic protein. Cox 
univariate regression analysis using logarithmically trans­
formed T P 53 protein values showed a significant (p < 0.001) 
positive association between TP53 protein concentrations and 
rate of relapse. This justified the search for cut-off points to 
classify tumors as TP53 protein-low and TP53 protein-high 
(accumulated). Different cut-off values were tested for their
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TABLE IX -  ISOTONIC REGRESSION ANALYSIS OF TP53 PROTEIN LEVELS
AND RELAPSE-FREE SURVIVAL
Range of TP53 
protein levels
Number of 
patients
Number of 
relapses
Mean time to 
relapse (months)1
0.00-0.02 14 7 139.1
0.03-0.09 4 2 129.1
0.10-0.18 8 4 123.5
0.20-2.40 54 33 103.3
2.69-5.84 13 10 65.1
5.90-23.50 13 10 49.0
26.32-26.32 1 1 12.6
41.94-48.96 2 2 4.1
87.26-175.96 2 2 3.7
’Sum of times at risk divided by number of re lapses during  th e  
full follow-up period.
ability to identify a subgroup of patients with TP53 accumula­
tion and poor prognosis. Isotonic regression analysis was 
applied with relapse-free survival as the end-point for all 
tumor samples (Table II), and a cut-off point was found at 2.5 
ng/mg protein to discriminate between TPS3 protein-high 
(28%) and TP53 protein-low (72%) cases.
Comparison o f LIA and SSCP
In 48 of 142 breast tumor samples (34%), a TP53 gene 
alteration was identified by PCR-SSCP analysis. An autoradio­
gram of SSCP analysis of exon 8 of the TP53 gene is shown in 
Figure 2. In 9 tumor samples, the TP53 gene mutation was 
demonstrated to be confined to exon 5, in 6 samples a mutation 
in exon 6 was detected and another 9 samples showed a 
mutation in exon 8. Mutations were most frequently observed 
in exon 7 (20 samples; Table III). One breast tumor sample 
was shown to contain 2 mutations, 1 in exon 5 and the other in 
exon 6, whereas 3 other samples had alterations in both exons 
6 and 8.
Mutations in the TP53 gene were compared with TP53 
protein levels as determined by LIA in the same tumor 
samples, using the cut-off point of 2.5 ng/mg protein. In 111 
cases (78%), an agreement was found between the outcome of 
the LIA test and SSCP analysis: in 83 tumor samples without a 
TP53 gene alteration, TP53 protein levels were below 2.5 
ng/mg protein, and in 28 samples with a mutated TP53 gene, 
elevated TP53 protein concentrations (> 2 .5  ng/mg protein) 
were measured. A different outcome was observed in 31 cases 
(22%); Le.t 11 samples without a gene alteration had high 
levels of TP53 protein and 20 samples with a gene alteration 
were shown to contain low TP53 protein levels.
In the 94 tumor samples without a TP53 gene alteration, 
TP53 protein levels ranged from 0 to 70.8 ng/mg protein 
(Table III). In samples with a mutation in the TP53 gene, TP53 
protein concentrations varied from 0.1 to 176,0 ng/m g protein 
and the median value was approximately 10 times higher, i.e., 
4.1 ng/mg cytosolic protein (Table III). Using the 2-sample 
Wilcoxon rank sum test, median TP53 protein concentrations 
differed in tumor samples with and without a TP53 gene 
alteration (p  = 0.0001).
TP53 protein expression vs. affected exon
Next, TP53 protein levels were investigated as a function of 
the mutated exon, analyses being confined to exons 5-8 (Table 
III). Cytosols from tumor tissues with a known alteration in 
exons 5-7 were quantitated to contain 2.0, 3.4 and 3.3 ng/mg 
protein (median values), respectively. Samples with a mutation 
in exon 8 contained the highest TP53 (median) protein levels,
i.e., 6.0 ng/mg protein (Table III). In the 4 samples with 2 
independent mutations; median TP53 protein concentration 
was 1.2 ng/mg (range 1.2-5.9 ng/mg; data not shown). Except 
for exon 5, the differences between TP53 protein levels in
samples with a mutation in a specific exon and without a TP53 
gene alteration were statistically significant (p  <  0.05), as 
analyzed by the Wilcoxon rank sum test (p  values corrected  fo r 
multiple comparisons). High TP53 protein levels (65.0 ng /m g  
protein) were measured in the T-47D cell line, which contains 
a mutated TPS3 gene. In contrast, cytosol prepared from  the 
ZR-75.1 cell line, with wild-type TP53, showed median cyto­
solic TP53 protein levels (0.4 ng/mg protein; data not shown).
TP53 expression in uni- and multi-vanate prognostic analyses
No significant associations of TP53 protein over-expression 
with age, menopausal and nodal status, tumor size or p ro g es te r­
one receptor status were observed. High TP53 protein levels 
were more frequently observed in tumors with low estrogen  
receptor content (p  =  0.03).
In univariate analyses, both TP53 gene alteration and TP53 
protein over-expression were significantly associated with in­
creased rates of relapse (p  = 0.013 and p < 0.001, re sp ec ­
tively; Fig. 3, top panels) and of death (p  — 0.026 and  
p < 0.0001, respectively; Fig. 3, bottom panels). In this p a tien t 
group, tumor size and low progesterone receptor con ten t w ere 
also associated with an increased rate of relapse (p  =  0.001 
and/? =  0.03, respectively). In multi-variate analyses, including 
age, menopausal status, tumor size, nodal status and estrogen 
and progesterone receptor status, TP53 protein over-expres­
sion (either dichotomized or as a continuous variable) was 
independently associated (p  <  0.01) with poor prognosis 
(Table IV). Relative relapse and death rates (with 95%  
confidence limits) were 2.38 (1 .34^.23) and 2.99 (1.57-5.68), 
respectively.
DISCUSSION
In the present study TP53 protein expression levels, as 
measured with a quantitative immunoassay, were com pared  
with the prevalence of TP53 gene alterations, as de tec ted  by 
SSCP analysis, in the same 142 breast tumor samples. In  34%  
of tumor samples, a TP53 gene alteration in exons 5 -8  was 
identified. This value falls within a range of frequencies 
(17-46%) reported earlier for TP53 mutations in p rim ary  
breast carcinomas (Runnebaum et aL, 1991; O sborne el al, 
1991), Samples with a TP53 gene mutation may give rise to  a 
protein with a highly stabilized conformation and, conse­
quently, an increased half-life as compared with wild-type 
TP53 protein (Levine et al., 1991). Using a cut-off po in t o f 2.5 
ng/m g protein, high cytosolic levels of TP53 pro te in  w ere  
observed in 28% of samples analyzed. Borg et al. (1995), who 
used the same LIA, found a lower cut-off value, b u t bo th  
studies showed TP53 protein over-expression in 30%  of 
tumors. A  significant correlation (p  -  0.0001) was found 
between TP53 protein over-expression and the presence o f  a 
TP53 gene alteration (exons 5-8). The highest (m edian) TP53 
protein level was found for tumor samples harboring a  m u ta ­
tion in exon 8 (but numbers are small). Interestingly, the high 
TP53 protein concentrations measured in cytosols p rep a red  
from the T47D cell line, which contains a mutated TP53 gene, 
clearly reflect the elevated TP53 mRNA expression observed 
on N orthern blots (not shown). The low levels observed in the 
cytosol from the ZR-75.1 cell line correspond to th e  p resen ce  
of the wild-type TP53 gene and, consequently, the low m R N A  
expression levels in the cells.
When dichotomized, a discrepancy was found be tw een  the 
results of both assays in 22% of the cases analyzed. T h e  
difference observed in 20 of 48 cases designated as being TP53 
protein-low  and TP53 gene-altered by SSCP analysis could be  
explained by mutations that do not lead to either stabilization 
of the protein or accumulation in the cells. As suggested  
previously, the level of TP53 protein expression m ay b e  
dependent on the type of mutation of the TP53 gene (B o d n e r
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F i g u r e  2 -  A utoradiogram  o f  PC R -SSC P analysis of exon 8 of the TP53 gene. L anes  with altered migration patterns are  indicated with 
an asterisk. HT29 serves as a positive control and  ZR-75-1 serves as a negative control. D, denatured ; N D , non-denatured  bands.
TABLE III -  RELATIONSHIP BETWEEN TP53 OVER-EXPRESSION, AS DETERMINED BY LIA, AND TP53 GENE
ALTERATIONS, AS ANALYZED BY PCR-SSCP
LIA/SSCP Number1 Median Range Mean SD LIA-low2 LIA-high2 Pvalue
W ild-type
M utant^
94 0.4 0.0-70.8 2.0 7.9 83 1 1 nnm
48 4.1 0.1-176.0 13.2 29.9 20 28 U.UUUl
Exon 5 9 2.0 0.1-41.9 7.0 13.3
Exon 6 6 3.4 0.2-13.0 5.3 5.6
Exon 7 20 3.3 0.3-176.0 22.9 19.0
Exon 8 9 6.0 0.2- 20.6 7.2 6.4
‘N u m b er o f cases .-2Cut-off point set at 2.5 ng/m g p ro te in .-3M utations in exons 5-8; 4 samples 
w ere shown to  contain  2 m utations (see “ R esu lts” ).
et cii, 1992), which is not disclosed by the SSCP analysis in this 
study. SSCP-positive tumors may include those with silent 
mutations as well as those with stop codons and deletions 
leading to expression of truncated protein, which is undetect­
able by immunological techniques (Greenblatt e/ al, 1994). We 
have therefore sequenced DNA from 14 DNA samples avail­
able out of the 20 SSCP-positive/LIA-negative samples. Of 
these, 4 samples showed deletions or insertions leading to an 
altered protein product. All 4 samples had low levels of 
protein. The other 10 DNA samples showed a silent mutation. 
Of these, 1 sample showed an elevated LIA level, another 
sample showed an LIA level of 2.5 ng/mg protein (cut-off 
point) and the remaining 8 samples showed low LIA levels, 
meaning that 12 of 14 were concordant. So far, it is not clear 
from our data that LIA will detect mutations of particular 
prognostic interest according to the data of Bergh et al (1995) 
or Borresen et al. (1995). Furthermore, proteins of viral origin, 
e.g., E6 oncoprotein, may target the TP53 protein to more 
rapid catabolism (Greenblatt et al., 1994), which leads to low 
TP53 protein levels.
The 11 cases (of 39) assigned as TP53 protein-high and not 
altered according to SSCP (28%) could be explained by the 
accumulation of TP53 protein in cytosols due to stabilization of 
the wild-type protein when forming complexes with other 
cellular or viral molecules. In these cases, accumulated wild- 
type TP53 protein would also be detected by the immunoassay 
since the LIA test utilizes MAbs specific for denaturation- 
resistant epitopes of the NH2-terminus of the protein, thus 
recognizing both mutant and wild-type TP53 proteins. More­
over, mutations may be present in other exons or introns or 
even in the regulatory gene sequences outside the regions 
screened by SSCP analysis, giving rise to high levels of TP53 
expression without evidence of a mutation. However, only a 
small percentage (below 10%) of the reported mutations have 
been found outside of exons 5-8 (Greenblatt et a l 1994). 
Another explanation could be accumulation of TP53 protein 
because of recent DNA damage from chemical and physical 
genotoxic agents (Greenblatt et al., 1994). Obviously, the 
cut-off point itself, selected because of the correlation of 
relapse-free survival with TP53 protein over-expression and
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Months Months
F i g u r e  3 -Actuarial relapse-free and overall survival curves for 111 primary breast cancer patients as a function of TP53 status. 
Relapse-free survival curves (upper panel) of patients with and without TP53 protein over-expression (left) and TP53 gene alterations 
fright^. Overall survival curves (lower panel) for patients with and without TP53 protein over-expression (left) and TP53 gene alterations 
(right). SSCP-alt and SSCP-norm indicate tumor samples with and without TP53 gene alterations in exons 5, 6, 7 or 8; LIA-low and 
LIA-high indicate TP53 protein expression below or above the cut-off point (2.5 ng/mg protein). Numbers in parentheses represent 
failures/total number of patients in each group.
TABLE IV-  COX MULTIVARIATE ANALYSIS FOR RELAPSE-FREE AND OVERALL SURVIVAL IN 111 PRIMARY
BREAST CANCER PATI ENTS
Relapse-free survival Overall survival
Factor p  value
multivariate R H R 1
p val u e 
multivariate RHRii
Age/menopausal status 
Age/pre-menopausal 
Age/post-menopausal 
Menopausal status 
Tumor size2
0.54
0.09 1.30 (0.96-1.76)
0.05
0.54
Lymph-node status3 
Nl-3 0.03 2.12(1.10-4.09) 0.24
N >3 0.01 2.25 (1.18-4.31) 0.04 2.10 (1.04-4.26)
Receptor status4 
Estrogen (ER) 
Progesterone (PgR) 
TP53 LI A result*
0.65
0.06
x. /
0.55 (0.30-1.02)
0.89
0.004
\  /  
0.36 (0.18-0.72)
0.003 2.38 (1.34-4.23) <0.001 2.99 (1.57-5.68)
Relative hazard rates with 95% confidence limits (values in parentheses) are presented for the 
variables with p < 0.10 in the multivariate analysis.-2Tumour size scored as T 1 -T 4 -3As compared 
to node-negative.~4Receptor-positive as compared with receptor-negative (cut-off points, 10 
fmol/mg protein)-5TP53 protein expression above 2.5 ng/mg protein as compared with TP53 
protein levels below the cut-olfvalue.
not with prevalence of TP53 gene mutations, also affects the 
agreement between the results of both assays. Nevertheless, 
the overall correlation between the outcome of both assays is 
highly significant (p  = 0.0001).
With respect to prognosis, TP53 protein accumulation 
appeared to be an independent predictor for both relapse-free 
survival and death. These findings complement the results of
both DNA-based and immunohistochemical investigations, 
which showed a strong association between either TP53 gene 
alteration or TP53 protein accumulation and poor prognosis 
(Elledge et a l, 1994; Andersen et aL> '1993; Boer et al.} 1995). 
Immunohistochemical analyses evaluate tumor tissue sections 
by estimating staining intensity and the percentage of stained 
cells. These results should be interpreted as semiquantitative
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(Greenblatt et aL, 1994). In contrast, SSCP, CGGE and 
DGGE analyses have a sensitivity and specificity of approxi­
mately 90% (Greenblatt et al, 1994) but are time-consuming 
and labor-intensive. The immunoassay applied in this study is 
easier and faster to perform and can be carried out on breast 
tumor cytosols routinely prepared for steroid hormone recep­
tor assays. Moreover, the immunoassay objectively quantitates 
TP53 protein expression, TP53 protein levels apparently being 
a reasonably good representation of both mutant and wild-type 
TP53 DNAs. Quantitative analysis of the TP53 protein status 
in cytosols routinely prepared for steroid hormone receptor 
analysis may contribute to the selection of patients who,
depending on the relationship of TP53 gene status with 
response to a specific type of systemic adjuvant therapy, could 
benefit from adjuvant therapy.
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